)
Pediatrix Medical Group (MD) investor relations material
Pediatrix Medical Group Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $501.4M, up 1.7% YoY; net income was $47.0M and Adjusted EBITDA was $85.5M, down from $71.7M and $87.3M, respectively.
9M revenue was $1.465B vs. $1.420B; Adjusted EBITDA rose to $220.1M from $209.7M, while net income fell to $116.4M from $131.7M.
Financial highlights
Q3 operating income was $65.2M, down 4.2% YoY; diluted GAAP EPS was $0.59 vs. $0.84, while Adjusted EPS rose to $0.72 from $0.67.
Q3 revenue growth reflected recent acquisitions net of dispositions and 0.6% same-unit growth; 9M same-unit revenue increased 2.0%.
9M operating income was $163.8M vs. $160.0M; Adjusted EPS was $1.78 vs. $1.54, while diluted GAAP EPS was $1.43 vs. $1.54.
Prior-year Q3 results included a $20.9M net gain on divested-business investments, excluded from Adjusted EBITDA and Adjusted EPS.
Outlook and guidance
FY 2026 Adjusted EBITDA guidance narrowed to $290M–$300M; management cited flexibility amid volume and pricing variability.
Operating cash, cash on hand and available credit were expected to fund obligations for at least 12 months from filing issuance; management expected debt-covenant compliance through 2026.
The Term A Loan matures in February 2027, with a final $171.9M payment due at maturity; 2027 coding-rule effects remain uncertain pending final rules and provider responses.
- Q2 2026 revenue grew 4% to $487.8M, with $76.4M EBITDA and continued share repurchases.MD
Q2 2026 - Q1 2026 revenue, earnings, and EBITDA rose, with guidance reaffirmed and strong liquidity maintained.MD
Q1 2026 - Annual meeting seeks votes on nine directors; Board supports all, proxy advisors note one attendance issue.MD
Proxy filing - Virtual meeting to elect directors, ratify auditor, and vote on executive pay and incentive plan.MD
Proxy filing - Proxy covers director elections, auditor ratification, pay, and incentive plan approval.MD
Proxy filing - Q4 2025 delivered strong EBITDA and net income, with 2026 EBITDA growth projected at 5%.MD
Q4 2025 - Q2 net loss of $153M from impairments; restructuring and new leadership target EBITDA growth.MD
Q2 2024 - Refocusing on core hospital-based care, with stable demand and growth in maternal-fetal medicine.MD
Jefferies Global Healthcare Conference - Adjusted EBITDA rose to $49.2M and guidance increased to $220–$240M for 2025.MD
Q1 2025
Next Pediatrix Medical Group earnings date
Next Pediatrix Medical Group earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)